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There is an urgent need to identify which COVID-19 patients will develop life-threatening illness so that med-
ical resources can be optimally allocated and rapid treatment can be administered early in the disease
course, when clinical management is most effective. To aid in the prognostic classification of disease
severity, we perform untargeted metabolomics on plasma from 339 patients, with samples collected at six
longitudinal time points. Using the temporal metabolic profiles and machine learning, we build a predictive
model of disease severity. We discover that a panel of metabolites measured at the time of study entry suc-
cessfully determines disease severity. Through analysis of longitudinal samples, we confirm that most of
thesemarkers are directly related to disease progression and that their levels return to baseline upon disease
recovery. Finally, we validate that these metabolites are also altered in a hamster model of COVID-19.
INTRODUCTION
Coronavirus disease 2019 (COVID-19), which is caused by infec-
tion with the novel coronavirus SARS-CoV-2, has led to a global
health crisis.1 To date, more than 150 million cases of COVID-19
have been reported worldwide and resulted in more than 3.2
million deaths.2 The infection-fatality rate of SARS-CoV-2 can
be reduced with the appropriate care (e.g., intensive care unit
beds, oxygen, staff, extracorporeal-life support, and therapeu-
tics). Unfortunately, hospital resources can quickly become
depleted in situations when cases spike.3 Although vaccination
efforts are underway worldwide, SARS-CoV-2 infections
continue to increase rapidly in a number of countries, such as In-
dia and Brazil, where medical facilities are being overwhelmed.4
Patients who develop critical illness from COVID-19 are best
treated early in the disease course before the onset of severe
symptoms.5,6 It is currently difficult to determine which subset
of patients will develop life-threatening disease and, therefore,
most benefit from receiving treatment when resources are
limited.7 Early identification of these patients would allow optimal
allocation of care. To that end, the objective of the current study
was to identify metabolites in patient plasma that accurately pre-
dict life-threatening cases of COVID-19 before the onset of se-
vere symptoms.
SARS-CoV-2 is an enveloped, single-stranded positive-sense
RNA virus that gains entry into host cells through binding of the
viral S protein to the angiotensin-converting enzyme 2 (ACE2) re-
ceptor.8,9 Multiple studies have established that patients in-
fected with SARS-CoV-2 havemetabolic dysregulation, possibly
because of immune-triggered inflammation or other changes in
host physiology.10–20 To date, however, unique alterations inme-
tabolites upon SARS-CoV-2 infection have not been validated in
large patient cohorts that have been profiled longitudinally from
early after infection through recovery. Longitudinal assessment
Cell Reports Medicine 2, 100369, August 17, 2021 ª 2021 The Author(s). 1
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
ll
OPEN ACCESS
of metabolic trends is necessary to assess which changes are
indicative of disease course.
In this study, we performed untargetedmetabolomics profiling
on the polar and non-polar fractions of 700 human plasma sam-
ples collected from 339 patients as part of the WU-350 cohort
recruited during the first phase of the pandemic in St. Louis,
Missouri. Untargeted metabolomics allows for the unbiased
profiling of the human metabolome21 and has been successful
at discovering metabolite biomarkers associated with disease
pathology.22 Using machine learning (ML), we built a model of
COVID-19 disease severity based on the metabolic profiles of
samples collected from patients at study enrollment. The model
led us to identify a panel of unique metabolite biomarkers that
were highly indicative of disease severity. We confirmed that
most of these metabolites were directly related to SARS-CoV-2
infections through comparison with patient demographics, co-
morbidities, clinical measurements, and longitudinal samples
taken from individuals over the course of disease progression.
Lastly, we validated that the same biomarkers appeared in an es-
tablished hamster model of SARS-CoV-2 infection.23–25
RESULTS
Clinical cohort WU-350: demographics
The clinical cohort presented in this study consisted of 155
female and 184 male participants. Of the 339 patients, 272
were considered SARS-CoV-2 positive (COV+) whereas 67
were considered SARS-CoV-2 negative (COV-). The COV+ and
COV- assignment of each individual was confirmed by nasopha-
ryngeal swab polymerase chain reaction (PCR). Significant dif-
ferences were observed in several demographic factors for the
COV+ cohort compared with the COV- cohort (Table 1). The
COV+ group contained significantly older study participants
(p < 0.0001; Figure S1A). The COV+ group also had significantly
more African American, male, and non-smoking individuals.
There was no significant difference in the body mass index
(BMI) between the two groups (Figure S1B).
Table 1. Demographics of all subjects
Parameter COV- COV+ p value
N 67 272
Gender (M/F) 28/39 156/116 0.0220




Body mass index 30 ± 8 31 ± 9 0.3987
COVID-19-like symptomsa
Any number of COVID19-like
symptoms
65 242 0.0437
Fever 29 128 0.5788
Chills 13 46 0.6300
Conjunctival congestion 1 1 0.2815
Nasal congestion 7 10 0.0229
Headache 18 23 <0.0001
Cough 35 147 0.7907
Sore throat 14 23 0.0034
Shortness of breath 44 168 0.5540
Nausea or vomiting 15 41 0.1487
Diarrhea 11 38 0.6098
Myalgia 16 66 0.9476
Fatigue 21 53 0.0353
Loss of taste or smellb 0 4 0.3180
Asymptomaticc NA 21
Acute respiratory failured 9 100 0.0002
Acute renal failured 2 68 <0.0001
Comorbidities
Chronic kidney diseasee 4 56 0.0050
Diabetese 15 120 0.0011
Cancere 8 24 0.4345
COVID-19 drug treatmentf
Remdesivir 2 43 0.0056
Dexamethasone 13 63 0.5087
High/Low arterial pH 5 83 0.0001
Current smoker 18 (27%) 36 (13.2%) 0.0063
Hospital admissiong 26 (38.8%) 252 (92.6%) <0.0001
ICU admissiong 10 (14.9%) 129 (47.4%) <0.0001
Intubation and mechanical
ventilation
4 (6.0%) 70 (25.7%) 0.0005
Deceased 6 (8.9%) 65 (23.9%) 0.0071
Deceased because of COVID-19h
30 day mortality N/A 39 (76.5%)
60 day mortality N/A 49 (96.1%)
90 day mortality N/A 50 (98.0%)
overall mortality N/A 51 (100%)
Table includesboth trainingand testcohorts.Percentagesare shownas the
percentage of the group (COV- or COV+). Demographic data were last up-
dated May 20, 2021. Data are presented as means ± SD, p values of
numeric parameters were calculated by using a two-tailed Student’s t
test with unequal variance, p values of categorical parameters were calcu-
lated by using a chi-square test. Abbreviations:M,male; F, female; N/A, not
applicable.
aTwo COV- individuals were without symptoms but were exposed to a
SARS-CoV-2-positive individual. Nine COV+ individuals had other symp-
toms (e.g., confusion, lethargy, an altered mental state, or breathing
anomalies). Clinical metadata last updated October 16, 2020.
bCDC guideline symptom was added to the symptom questionnaire late
in the study; parameter is not available for most of the subjects.
cA SARS-CoV-2 test was routinely administered at presentation to the
hospital for reasons other than COVID-19 (e.g., accidents, pre-operation
tests, regular checkups, cancer screening, injuries, or exposure to a
SARS-CoV-2-positive individual).
dDuring present hospitalization.
eRecorded up to 1 year before the current admission or up to 1 year
before the d0 sample for those who were not admitted to the hospital.
fAt any point during hospital stay.
gHospital and/or ICU admission of COV group was for reasons other
than COVID-19 (e.g., accidents, acute respiratory failure from bacterial
pneumonia, intentional self-harm, possible heart failure, hypertension,
trauma, and cancer).
hPercentages shown as the percentage of total number of patients who
died of COVID-19.




Of the 272COV+ individuals, 252were admitted to the hospital
and 129 of those patients were admitted to the intensive care unit
(ICU). As expected, the incidence of both factors (hospitalization
and ICU admission) was significantly increased in the COV+
cohort. Treatment of severe COVID-19 cases often results in
intubation and mechanical ventilation.26 In total, 70 of the
COV+ patients required mechanical ventilation, whereas only
four COV- individuals required mechanical ventilation. The ther-
apeutics administered to treat COVID-19 in this cohort were
dexamethasone and remdesivir. In total, 43 COV+ patients
were treated with remdesivir and 63 with dexamethasone during
their hospital stay (Table 1). The mortality rate in the COV+ group
was 23.9%, which was significantly higher than the 8.9%mortal-
ity rate in the COV- group. A total of 65 COV- patients died, with
51 of the deaths being attributed to COVID-19 and 14 being
attributed to other causes.
Of the 272COV+patients, 242 showed at least one COVID-19-
related symptom mentioned by the Centers for Disease Control
and Prevention (CDC), including fever, chills, conjunctival
congestion, nasal congestion, headaches, cough, sore throat,
shortness of breath, nausea or vomiting, diarrhea, myalgia, fa-
tigue, and loss of taste or smell.27 Of the remaining COV+ cases,
21 showed no symptoms and were classified as asymptomatic.
Nine subjects in the COV+ group displayed other symptoms,
such as confusion, lethargy, an alteredmental state, or breathing
anomalies. Of the 67 COV- cases, 65 presented with at least one
COVID-19-related symptom upon study entry, whereas two
received a SARS-CoV-2 PCR test upon exposure to a SARS-
CoV-2-positive individual. The frequency of COVID-19-related
symptoms is shown in Table 1, and the distributions across the
COV+ and COV- cohorts are depicted in Figure S1C. In both
the COV- and COV+ groups, the number of COVID-19-related
symptoms reported per individual was comparable. The break-
down of how many symptoms were experienced per individual
in both the COV+ and COV- groups is shown in Figures S1D
and S1E.
Next, we examined the distribution of comorbidities and self-
reported medical history presented in the WU-350 cohort. Med-
ical conditions were assigned based on ICD10 codes and the
Elixhauser naming conventions.28 Chronic kidney disease
(CKD) and diabetes (recorded up to 1 year before the current
admission and up to 1 year before the day 0 (d0) sample for those
who were not hospitalized) was significantly higher in the COV+
group compared with the COV- group (Table 1). The incidence of
acute renal failure and acute respiratory failure during the pre-
sent hospitalization was also significantly elevated in the COV+
group compared to the COV- group (Table 1). Furthermore,
31% of the COV+ individuals showed an abnormal arterial pH
(acidosis or alkalosis) compared with 7.5% in the COV+ group.
Of individuals in the COV+ group, 23.9% are now deceased.
Of the COVID-19-related deaths, 76.5% occurred within
30 days, 96.1%within 60 days, and 98%within 90 days of study
entry.
Study design
Blood was collected from study participants directly after enroll-
ment in the WU-350 study (d0). Further longitudinal samples
were collected 3 (d3), 7 (d7), 14 (d14), 28 (d28), and 84 (d84)
days after the initial blood collection, when possible. The collec-
tion of longitudinal samples depended on survival of the study
participants as well as the participants’ ability to complete study
visits after being discharged from the hospital. A total of 703 hu-
man plasma samples from 341 patients were available for me-
tabolomics profiling, including 324 d0 samples, 164 d3 samples,
111 d7 samples, 54 d14 samples, 31 d28 samples, and 19 d84
samples. All samples were divided into nine randomized sample
batches and analyzed by liquid chromatography/mass spec-
trometry (LC/MS). An extract of the standard reference material
(SRM) 1950 fromNIST (National Institute of Standards and Tech-
nology, Metabolites in Frozen Human Plasma) was measured
repeatedly as a quality control (QC), and blank samples were
used to assess background signals. Polar and lipid metabolite
fractions were extracted from each sample, and a global metab-
olomics profile was acquired in both positive and negative ion
modes. Processing of the data led to the putative identification
of 235 polar and 472 lipid metabolites based on accurate mass
and MS/MS matching. Peak areas were extracted for those
707 metabolites to form the metabolic profile of each patient.
Given that the metabolic profiles were acquired over several
months, the combined data showed strong batch effects as
demonstrated by the principal component analysis (PCA) in Fig-
ure S2A. To remove the variance introduced by the individual
batches, but not lose the differentiating biological variancewithin
the research (WU-350) samples, we tested several normalization
approaches (Figure S2B) and selected a combined batch
correction (ComBat)29 approach that outperformed the other
common normalization approaches tested (e.g., probabilistic
quotient normalization, unit length, constant sum, quantile,
etc.). After normalization, the metabolic profiles retained differ-
ences according to sample origin (WU-350, QC, and blank) as
shown in Figure S2C but no longer clustered based on batch
(Figure S2D).
The goal of this study was to findmetabolic alterations that are
predictive of disease severity in SARS-CoV-2-positive individ-
uals. We used admission to the ICU during disease progression
to classify patients as having severe or non-severe disease, as
has been done previously.30,31 An ideal set of predictor metabo-
lites would allow an individual presenting at the hospital and
receiving a positive SARS-CoV-2 PCR-test result to be assessed
for the likelihood of severe disease progression to best guide
treatment at the earliest stage of hospitalization. Thus, we group-
ed the presented COV+ cohort into a non-severe (COV+ non-se-
vere) group that did not require ICU admission and a severe
group (COV+ severe) that did require ICU admission. For data
interpretation purposes, three samples were excluded as the
specimens originated from two patients who tested positive for
other coronaviruses (NL63, HKu1). The final patient cohort con-
sisted of 67 COV- cases, 143 COV+ non-severe cases, and 129
COV+ severe cases. Unsupervised analysis of the metabolic
profiles for the 322 d0 samples available in our patient cohort
demonstrated a clear trend in principal components space that
separated COV+ severe, COV+ non-severe, and COV- patients
(Figure 1A). Further, several significantly varying metabolites
suggested that the metabolic profiles at d0 may indeed be pre-
dictive of disease severity. Hierarchical clustering analysis
(HCA) of the 54 statistically significant metabolites (p < 0.05,




Welch’s ANOVA) with an absolute fold change greater than two
when compared with the COV- group revealed striking changes
in multiple representatives of lipid classes, including lysopho-
phatidylcholines (LPCs), phosphatidylcholines (PCs), and tri-
glycerides (TGs). Further, several polar metabolites known to
be related to COVID-19, including gluconate32 and dimethylgua-
nosine,33 were also significantly altered (Figures 1B and S3).
Predictive model of COVID-19 disease severity
The global trends in the d0 metabolic profiles visible in the PCA
and HCA visualizations prompted us to develop an ML model of
disease severity that would predict ICU admission caused by
SARS-CoV-2 infection. Patients presented to the hospital and
enrolled in the study at different times during their disease
course, hence the d0 sample is variable with respect to days-
post symptom onset. The time from patient-reported symptom
onset to d0 sample collection ranged from 0 to 107 days, with
4 days being the median. In addition, 45 of the COV+ patients
were on mechanical ventilation and 98 COV+ patients were
admitted to the ICU when the d0 sample was collected (Fig-
ure S4A). Although this diversity added additional variance to
the d0 metabolic signatures, it also enabled a more clinically
Figure 1. Study design
(A) Principal component analysis based on all polar (n = 235) and lipid (n = 472) metabolites in SARS-CoV-2-negative individuals (COV-, n = 59, green), SARS-
CoV-2-positive individuals with non-severe disease (COV+ non-severe, n = 140, orange), and SARS-CoV-2-positive individuals with severe disease (COV+
severe, n = 123, red). Data shown are only from the sample provided during study entry(d0).
(B) Hierarchical clustering analysis of metabolic profiles of COV-, COV+ non-severe, and COV+ severe patients at d0. Represented are 54 significantly changing
polar and lipid metabolites (p < 0.05, Welch’s ANOVA, Benjamini-Hochberg correction). Each column is a sample, and each row is a metabolite. Cell color
corresponds to the normalized metabolite intensity in each sample.
(C) Human cohort of 67 SARS-CoV-2-negative and 272 SARS-CoV-2-positive participants. The cohort was divided into a training cohort and a test cohort. The
study design incorporated six blood draws for SARS-CoV-2-positive individuals on days 0 (d0), 3 (d3), 7 (d7), 14 (d14), 28 (d28), and 84 (d84) after WU-350 study
entry.




relevant model to be constructed because patients will present
to the hospital at various points in the disease course. We note
that COV+ severe and non-severe patients were not significantly
different in time from symptom onset to the d0 sample collection
(Figure S4B). The 707 metabolites that composed the metabolic
profiles served as the predictors for our ML model. To assess
predictive power, we split our dataset into two distinct groups
of COV+ patients: a training set (163 patients) that we used to
select, optimize, and train our ML model and an independent
test set (100 patients) that was only used to evaluate the model’s
performance (Figure 1C; Tables S1 and S2). Using our training
set, we evaluated the efficacy of five ML algorithms with 20-
fold cross-validation and found that a linear ElasticNet34 regres-
sionmodel was themost effective (Figure S4C). After training the
model, we applied it to the patients in the test set and assessed
performance by using the area under the receiver operating
characteristic curve (AUC). On the test set, we saw strong pre-
dictive performance (AUC = 0.72) that outperformed a simple
model that only uses BMI and age to predict disease severity
(Figure 2A) and is significantly more predictive than a random
model (Figure 2B, see permutation test in method details). As
Figure 2. Predicting SARS-CoV-2 severity
by machine learning
(A) Receiver operating characteristic (ROC) curves
of prediction model on training set (green) and
test set (blue). Random performance is shown in
gray. ROC of BMI and age as predictors for
severe COVID-19 (red) results in nearly random
performance.
(B) Permutation test results from permuting
training set labels and training the model on the
permuted data. With every permutation, the area
under the ROC curve (AUC) for the test set was
computed. The histogram shows the distribution
of these AUC values for 1,000 random permuta-
tions. Themodel performance on the test set when
trained on the non-permuted training data results
in an empirical p value of 0.002, as shown in blue.
(C) Variable importance in reduced ElasticNet
prediction model for disease severity of SARS-
CoV-2 infection in humans. Negative values are
predictive of non-severe disease and positive
values are predictive of severe disease. Variable
importance is after the model is trained on the
complete dataset.
(D) Profile plot of the normalized intensity (d0) of
the prediction model metabolites grouped into
COV- (control, n = 59), COV+ non-severe (n = 140),
and COV+ severe (n = 123). The color of the lines
reflects the mean intensity of each metabolite in
the COV- patients.
(E) Boxplots showing predictor metabolite in-
tensities (d0) in the COV-, COV+ severe, and
COV+ non-severe groups. Box limits represent the
quartiles of each sample group. Whiskers are
drawn to 1.53 of the inter-quartile range.
further validation, when the trainedmodel
was applied to the COV- patients (no
COV- patients were in the training set),
the mean scores output by the model
were lower than those for the COV+ non-severe and the COV+
severe patients in the test set (Figure S4D). This indicates that
the model can differentiate disease severity and distinguish
COV+ and COV- patients. We wish to emphasize that PCR is
the gold standard to diagnose SARS-CoV-2 infection. As such,
we present this result only as confirmation that our model
correctly predicts disease severity and not as a potential diag-
nostic for viral infection.
We next sought to interpret which metabolites were most
salient to the model’s predictions. First, we computed the vari-
able importance of the model when trained on the complete da-
taset, which found 92 unique metabolites that contributed to the
model’s predictions. Among that group of 92 compounds were
metabolites that have been previously implicated in SARS-
CoV-2 infection, such as kynurenate, nicotinamide, creatinine,
LPCs, PCs, and others.11,12,14,32 The mean intensity of each
metabolite in the COV-, COV+ non-severe, and COV+ severe
groups can be seen in Figure S5. Next, we aimed to assess
the robustness of the metabolites selected by the ML model.
We used bootstrap resampling of our training dataset to
construct confidence intervals for the variable importance of




Figure 3. COV+ patient parameters
(A–I) Demographics, comorbidities, and laboratory values of SARS-CoV-2-positive individuals grouped by disease severity (non-severe, severe) for age (A), BMI
(B), CO2 (C), C-reactive protein (D), D-dimer (E), absolute neutrophil levels (F), neutrophil percentage (G), absolute lymphocyte levels (H), and lymphocyte per-
centage (I). Statistical significance (p < 0.05) was assessed by using a two-tailed Student’s t test with unequal variance for data shown in (A-I).
(J) Proportion of COV+ severe and non-severe patients with specific comorbidities and laboratory test results.
(K) Pearson correlation of listed demographic/laboratory results/comorbidities with abundances of the predictor metabolites.
(legend continued on next page)




each of the 707metabolites we profiled.35 The analysis led to the
identification of 22 predictor metabolites that significantly
contributed to the model’s fit. The structural identities of these
metabolites were rigorously confirmed (see method details).
Strikingly, manyof the predictor metabolites were LPCs. Using
the reduced predictor set, we re-trained and re-optimized our
ElasticNet model on the training set and assessed the predictive
power on our test set. Using the reduced predictor set resulted in
nearly an identical AUC to that of the full set of metabolites
(AUC = 0.70) and still performed better than a random model
or a model that used only BMI and age as predictors (Figures
S6A and S6B). To ensure that our model is indeed capable of
predicting future disease severity, we additionally evaluated
our model on the portion of the test-set patients who were not
admitted to the ICU on or before when the d0 sample was
collected. We again found that our model’s performance re-
mained high (AUC = 0.71) and continued to outperform a model
based only on BMI and age (Figures S6C and S6D). The variable
importance of the predictor metabolites when trained on the
entire dataset is shown in Figure 2C. The mean intensity of the
metabolites in the COV-, COV+ non-severe, and COV+ severe
groups is shown in Figures 2D and S7. In addition, the intensities
of these metabolites among test-set patients and patients not
admitted to ICU on d0 are provided in Figure S8. To exclude
the possibility that the metabolite alterations were due to the
application of therapeutics, we additionally removed all d0 sam-
ples when dexamethasone or remdesivir were administered on
the same day as sample collection. Using that subset, all predic-
tor metabolites were still significantly altered. All LPCs and PCs
that contributed to the model, as well as serine, presented a sig-
nificant downward trend in signal abundance with disease
severity. Conversely, the other polar metabolites (kynurenate
and 1-methyladenosine), phosphatidylethanolamines (PEs),
and ceramides exhibited a significant upward trend in signal
intensity (Figure 2E).
Demographics, laboratory values, comorbidities, and
COVID-19 severity
After evaluating the efficacy of the ML model, we wished to
deduce the relationship of our metabolite predictors to COVID-
19 disease severity. We examined whether these metabolites
were reflective of an underlying condition/risk factor for severe
disease or if they were related to the disease progression of
COVID-19. We addressed the former by asking whether any of
the predictor metabolites correlated with demographic factors,
laboratory values, current severity predictors, or individual pa-
tient comorbidities available for the patient cohort. A comparison
of the COV+ non-severe and severe groups identified several
significantly different parameters (Table S3). The COV+ severe
group was significantly older than the non-severe group (Fig-
ure 3A), but therewas no significant difference in BMI (Figure 3B).
CO2 levels were not significantly altered between groups (Fig-
ure 3C), with valuesmostly being in the normal range. In contrast,
there were significantly increased levels of the inflammatory
marker C-reactive protein (CRP; Figure 3D). D-dimer, absolute
neutrophil count, and neutrophil percentage were also increased
(Figures 3E–3G). Absolute lymphocyte count and lymphocyte
percentage were decreased (Figures 3H and 3I). These data indi-
cate more severe inflammation in the COV+ severe group
compared with the non-severe group and are consistent with re-
ports from previous studies.11,36,37 Neutrophil recruitment has
also been shown to be dysregulated in severe cases of
COVID-19.38–41 Lymphopenia, abnormally low levels of blood
lymphocytes, has been found to correlate with disease severity
in COVID-19 and even to be predictive of disease severity.42–46
Given that specific comorbidities increase the risk of having a
severe case of COVID-19,31,47,48 we asked which co-morbidities
were enriched in the COV+ severe group compared to the COV+
non-severe group (Figure 3J; Table S3). Diabetes, cancer, and
chronic kidney diseases were recorded up to 1 year before hos-
pital admission or up to 1 year before the d0 samples for non-
hospitalized individuals. Although diabetes was significantly
more prevalent in the COV+ group, the number of individuals
with cancer and/or chronic kidney disease was not significantly
different between the groups. Because acute respiratory failure
and/or acute renal failure is a feature of severe COVID-19, the
proportion of individuals suffering from either or both is signifi-
cantly greater in the COV+ severe patients. Further, laboratory
tests showed an increased proportion of individuals having an
abnormal arterial pH (acidosis or alkalosis) in the COV+ severe
group compared to the COV+ non-severe patients. The pre-
sented laboratory results (arterial pH, neutrophils, lymphocytes,
D-dimer, CRP, and CO2) were obtained within 48 h of the first
sample after study entry (d0).
Considering the number of significant associations in the pa-
tient parameters between COV+ severe and non-severe pa-
tients, we wanted to test whether any of our predictor metabo-
lites significantly correlated with the clinical data after we
controlled for disease severity (method details). To that end,
we computed the Pearson correlation49 (for continuous parame-
ters) or the point biserial correlation50 (for binary parameters) be-
tween each predictor metabolite and patient parameter (Fig-
ure 3K). The analysis revealed that many of the patient
comorbidities were not significantly associated with the predic-
tor metabolites. Smoking, BMI, and cancer were not significantly
correlated with any of the predictor metabolites. Age and CKD
had weak correlations with 1-methyladenosine (r = 0.32, 0.33),
kynurenate (r = 0.20, 0.36), and serine (r = 0.19, 0.15). Ky-
nurenate has been described previously51 as being associated
with CKD. The most striking results are the significant positive
correlations of the PEs (r = [0.20, 0.23], [0.26, 0.37]), ceramides
(r = [0.14, 0.21], [0.26, 0.43]), and 1-methyladosine (r = 0.26,
(L) Pearson correlation of interleukin levels with abundances of predictor metabolites. Cells in the heatmaps (K and L) shaded white do not have a statistically
significant Pearson correlation (p < 0.05, Benjamini-Hochberg correction).
(M) AUC values for patient comorbidities, demographics, laboratory values, the metabolite model, and a model that uses both the metabolites and laboratory
values (absolute lymphocyte, absolute neutrophil, CRP, and D-dimer) when predicting disease severity on the test-set patients with complete information for all
patient parameters.




0.20) with inflammatory markers (neutrophils and CRP) as well as
the incidence of acute renal failure and diabetes. The PEs (r =
[0.07, 0.05]), ceramides (r = [0.14, 0.12]), and 1-methyla-
denosine (r = 0.21) were also negatively correlated with
lymphocyte levels, suggesting that these metabolite changes
may be associated with inflammation. The LPCs, PCs, and
serine showed the opposite trend as the PEs and ceramides.
These molecules had positive associations with lymphocyte
levels (r = [0.15, 0.34]) and negative associations with CRP (r =
[0.37, 0.23]) and neutrophil levels (r = [0.28, 0.08]), sug-
gesting that they too are associated with inflammation. We
further correlated severity-associated interleukin levels that
have been reported for a portion of our cohort in a prior publica-
tion (Figure 3L).52 Interleukin 6 (IL-6) levels, which have previ-
ously been shown to be a marker for disease severity,53–55
were inversely correlated with LPCs, PCs, and serine after
controlling for severity (r = [0.43, 0.26]). Similarly, 1-methyla-
denosine (r = 0.47), kynurenate (r = 0.44), Cer-NS d18:1_16:0
(r = 0.32), and PE 16:0_18:2 (r = 0.22) had significant positive cor-
relations with IL-6, giving further evidence that many of the
metabolite alterations are related to inflammation.
We then sought to assess the predictive power of our ML
model relative to the predictive power of the patient comorbid-
ities and laboratory values collected within 48 h of the d0 sample
(CRP, D-dimer, neutrophil, and lymphocyte levels). For each pa-
tient parameter, we computed the AUC when predicting disease
severity for each patient in the test set without missing values for
any of those parameters (n = 68; Figure 3M). For all evaluated co-
morbidities, the model achieved a higher AUC. Conversely, the
laboratory values (D-dimer, CRP, neutrophil, and lymphocyte
levels) were all more predictive of disease severity than the
metabolite model. However, when a new model was trained
that used these laboratory values in combination with the
biomarker metabolites, the performance of the combined model
(AUC = 0.77) outperformed both the metabolite model (AUC =
0.66) and each laboratory value (AUC = [0.72, 0.73]), suggesting
that the metabolite model is capturing complementary informa-
tion to the laboratory values. In total, these results suggest that
our predictor metabolites are indeed relevant to the pathogen-
esis of SARS-CoV-2 infection and not merely markers of other
risk factors.
Longitudinal progression of predictor metabolites
To give further confidence that our predictor metabolites are
associatedwith COVID-19 pathogenesis, we aimed to determine
how the levels of these metabolites changed over the course of
the disease progression. First, we considered the portion of the
COV+ severe cohort that survived SARS-CoV-2 infection. We
sought to determine the temporal behavior of their metabolic
profiles as patients reached peak disease severity and after re-
covery. Accordingly, we analyzed the longitudinal metabolite
abundances from individuals who had severe disease but sur-
vived andwere discharged from the hospital. We compared their
initial d0 plasma sample to the sample taken closest to the day of
ICU admission, when the disease had progressed to peak
severity. We also compared their initial d0 plasma sample to
the last sample provided by the patient at or after hospital
discharge. For several LPCs and one PC, a V-shaped trend
Figure 4. Course of disease progression
(A)Predictionmodelmetabolites that significantly vary in intensityasa functionof
disease progression for SARS-CoV-2-positive patients surviving severe disease
(COV+ severe). d0 denotes the first sample after hospital admission, ICU de-
notes the sample collected closest to ICU admission, and the last sample is the
final sample collected for the patient. Only patients for whom these time points
were distinct samples were plotted. Statistical significance was assessed by a
repeated-measures one-way ANOVA with a Benjamini-Hochberg correction.
(B) Principal component analysis showing the trajectory of the meanmetabolic
profile of the predictor metabolites in COV+ non-severe patients, surviving
COV+ severe patients, and deceased COV+ severe patients. Deceased and
surviving status was based on 90-day mortality. Patient samples were binned
based on days post symptom onset (0–3, 4–6, 7–11, 12–18, 19–40, and 41–
100). Samples taken when dexamethasone or remdesivir were administered
were excluded. Asymptomatic patients were excluded. The mean d0 meta-
bolic profile of COV- patients is shown in green.




was observed (Figure 4A). After the initial sample (d0), the levels
of these metabolites dropped further as the disease worsened,
but then began to return to d0 levels during recovery. The reverse
trend was observed for Cer-NS d18:1_16:0. Its levels signifi-
cantly increased until the patients were admitted to the ICU,
but its levels subsequently dropped to below the initial d0 values
in the final sample obtained.
These pronounced longitudinal trends in surviving COV+ se-
vere patients raised the question of how the trajectory of disease
progression (as marked by our predictor metabolites) differed
among COV+ non-severe patients, surviving COV+ severe pa-
tients, and deceased COV+ severe patients. We also sought to
compare the end points in these groups to the COV- d0 patients.
We constructed representative metabolite profiles for the groups
by using the levels of the predictor metabolites at different time
windows relative to symptom onset (0–3, 4–6, 7–11, 12–18,
19–40, and 41–100 days post symptom onset) and performed
a principal component analysis that enabled the trajectory of
each group to be visualizedin two dimensions (Figure 4B). Sam-
ples from asymptomatic patients or patients administered the
COVID-19-related therapies dexamethasone or remdesivir on
the day of sample collection were excluded from this analysis.
Notably, the analysis revealed three distinct trajectories with
starting points that trended with disease severity. The groups
then followed a common trajectory toward the COV- d0 sample.
Figure 5. Longitudinal trends in COV+ pa-
tients
(A) Profile plot of the mean predictor metabolite
intensities relative to d0 COV- samples (n = 59,
gray) in symptomatic SARS-CoV-2-positive in-
dividuals with severe COVID-19 (n = 123, COV+
severe).
(B) Profile plot of the mean predictor metabolite
intensities in symptomatic SARS-CoV-2-positive
individuals with non-severe disease (n = 140,
COV+ non-severe).
(C and D) Heatmaps showing relative mean in-
tensity of predictor metabolites in longitudinal
profiles of symptomatic COV+ severe patients (C)
or COV+ non-severe patients (D). The mean COV-
d0 profiles are included as the control for refer-
ence. Patient samples were grouped based on
symptom-onset windows. Patient samples where
dexamethasone or remdesivir were administered
were excluded from the analysis. Asymptomatic
patients were excluded. *p < 0.05. Statistical sig-
nificance was assessed by using a one-way
Welch’s ANOVA with a Benjamini-Hochberg
correction.
However, the COV+ non-severe patients
recovered much quicker than the COV+
severe patients, reaching a similar meta-
bolic profile to the d0 COV- patients in
less than 40 days post symptom onset.
The deceased COV+ severe patients
had a similar metabolic profile during
the 41–100 day window when compared to surviving COV+ se-
vere patients. These results point toward distinct metabolic pro-
grams associated with the time course of infection and disease
outcome. When examining the individual metabolite levels within
the four groups at each time window, the deceased COV+ se-
vere patients showed the same direction of dysregulation across
the predictor metabolites as the surviving COV+ severe patients,
but the magnitude of the perturbation was increased. In the 41–
100 day window, less than 20% of the predictor metabolites
were significantly altered, suggesting that metabolite levels
return to control levels over time (Figure S9).
Next, we sought to compare the longitudinal progression of
the predictor metabolites between the surviving COV+ patients.
In the COV+ severe group, the LPC levels increased over the dis-
ease course to levels that were comparable to the COV- group
(Figure 5A). In the COV+ non-severe group, the LPC levels recov-
ered faster, reaching control levels in less than 40 days post
symptom onset (Figure 5B). In total, 15 of the predictor metabo-
lites showed a significant change (p < 0.05, Welch’s ANOVA)
across the longitudinal time points in the COV+ severe group
(Figure 5C). Of the LPCs, 11 were significantly increased over
time. PC 38:6, PC 20:4_20:4, and PC 18:2_22:6 were also signif-
icantly increased with time. After initially being increased
compared to the d0 sample of the COV- group, kynurenate
showed a significant decreasing trend. Because of the lower




sample numbers, the COV+ non-severe group had only six me-
tabolites (five LPCs and one PC) that showed a significant trend
(p < 0.05, Welch’s ANOVA; Figure 5D).
Syrian hamster model confirms metabolite changes in
COVID-19
Lastly, we aimed to validate that the predictor metabolites we
found in the human samples were directly related to COVID-19
and not to some unidentified correlate that could have
confounded our analysis. As such, we used an established ham-
ster model of SARS-CoV-2 infection.24,25 Syrian hamsters have
been found to be susceptible to SARS-CoV-2 infection, with
the virus mainly replicating in the upper and lower respiratory
tract of intranasally challenged animals for approximately
6 days post infection. Diseased animals exhibit a loss of body
weight and pathological lung inflammation. We obtained plasma
samples from golden Syrian hamsters that were intranasally
inoculated with SARS-CoV-2 according to Imai et al.,25 influenza
virus according to Iwatsuki-Horimoto et al.,56 or nasally treated
with saline solution as a mock infection. Viral infection of the
lung and body-weight loss were confirmed in all SARS-CoV-2-
and influenza-infected hamsters and were consistent with previ-
ous reports.25,56 All SARS-CoV-2-infected hamsters experi-
enced greater body-weight loss (>5.1% of their initial body
weight) compared to influenza-infected hamsters, and virus
was detected in both the lungs and nasal cavity in both models
(see method details; Figure S10).
After 2, 4, 6, and 14 days (d2, d4, d6, and d14) post infection,
plasma was harvested from the SARS-CoV-2- and influenza-in-
fected hamsters (Figure 6A) because those time points correlate
with the well-established kinetics of pathology and infection in
the hamster model of SARS-CoV-2.24,25,57 For the mock group,
plasma was harvested on days 4 and 14 relative to the infection
timeline. All plasma samples were subjected to the same LC/MS
workflow as described above. Differences in the sample matrix
prevented a direct comparison of metabolite intensities between
rodent and human plasma, but we are able tomake comparisons
between the different experimental groups. We compared the
Figure 6. Syrian hamster model confirms SARS-CoV-2-dependent metabolite changes
(A) Experimental design of the Syrian hamster model. Hamsters (n = 3–6 per group) were infected through intranasal inoculation of SARS-CoV-2 (1e5 plaque-
forming units [PFUs]), influenza virus (1e5 PFU), or nasally treated with a saline solution (mock) on day 0 (d0). After 2, 4, 6, and 14 days (d2, d4, d6, and d14) post
infection, animals were sacrificed and exsanguinated.
(B) Comparing metabolite intensities among hamsters infected with influenza (n = 6), SARS-CoV-2 (n = 5), and mock (n = 6) on d4 shows many of the predictor
metabolites are significantly altered in the hamstermodel (p < 0.05,Welch’s ANOVA). Box limits represent the quartiles of each sample group.Whiskers are drawn
to 1.53 of the inter-quartile range.
(C and D) Metabolite changes during disease progression in SARS-CoV-2 (C) and influenza (D). Infected animals show a faster recovery during influenza. All
groups are n = 6with the exception of SARS-CoV-2 hamsters at d2 (n = 3) and d4 (n = 5). *p < 0.10, **p < 0.05. Statistical significancewas assessed by using a two-
tailed Student’s t test with unequal variance between d2 and d4 samples. All values were corrected with the Benjamini-Hochberg procedure.




predictor metabolite levels of samples from the three groups
(SARS-CoV-2, influenza, and mock) harvested on d4 as a repre-
sentative time point for early disease. Figure 6B shows the 11
significantly changing predictor metabolites (p < 0.05, Welch’s
ANOVA) across the three groups. Of the LPCs, eight were signif-
icantly altered in animals infected with SARS-CoV-2. Although
PC 20:4_20:4 was not detected in the hamster plasma, possibly
because of matrix effects, the two detected PCs were signifi-
cantly dysregulated, along with PE 16:0_20:4. All 11 of the signif-
icantly altered metabolites showed the same direction of dysre-
gulation as what was observed in the d0 human samples. For all
significantly varying metabolites except PE 16:2_20:4, infection
with the influenza virus showed a similar trend of dysregulation
relative to control samples but a very different magnitude
compared to SARS-CoV-2 infection. This is consistent with
milder disease in influenza-infected hamsters compared to ham-
sters infected with SARS-CoV-2 and suggests that the depres-
sion of LPCs and PCs may not be as specific to SARS-CoV-2
infection as changes in PEs.
Finally, we wanted to determine whether the predictor metab-
olites in hamsters showed longitudinal changes over the time
course of infection. Indeed, when compared to the d4 control
(mock infection) samples, there was a similar trend in hamsters
infected with SARS-CoV-2 (Figures 6C and S11A) as in human
COV+ samples. There was minimal time-dependent variation in
the mock-infection samples, and none of the predictor metabo-
lite levels were significantly different between d4 and d14 in
those animals (Figure S11B). In SARS-CoV-2-infected hamsters,
plasma LPC levels decreased on d4 compared to d2 and slowly
recovered toward the control levels on d14. By comparison, for
the influenza-infected animals, metabolite levels approached
those of the control group more rapidly (Figures 6D and S11C).
The similar patterns of alteration and recovery in LPC and PC
levels across both hamsters and humans suggest that these lipid
species are directly related to SARS-CoV-2 infection.
DISCUSSION
The current study sought to predict COVID-19 disease severity
based on the metabolic profiles of human plasma samples ob-
tained early in the disease course, before the onset of critical
illness. We applied untargeted metabolomics to profile a patient
cohort of 339 individuals, which amounted to 700 study samples
in addition to QC and method blanks. From the experiments, we
putatively identified 235 polar metabolites and 472 lipid species.
Using these compounds, we applied ML techniques to build a
predictive model that accurately classified a patient’s disease
severity from their d0 metabolic profile obtained at the time of
initial study entry. Currently, risk assessment is primarily based
on BMI and age.58 Even though we see a significant difference
between the ages of patients in the non-severe and severe dis-
ease groups (p < 0.0001), the results of our study show that
risk assessment based on a small panel of predictor metabolites
is more reliable than age and BMI, thereby providing a better
metric for resource allocation.
Although our linear ElasticNet model is relatively simple
compared to other popular ML models that have been applied
to metabolomics datasets previously (including artificial neural
networks, support vector machines, or ensemble-based ap-
proaches, such as random forest), linear models can be easily in-
terpreted and provide robust performance even when modeling
innately non-linear biological systems.34,59 Notably, a previous
study13 successfully used an ElasticNetmodel to predict disease
severity from amulti-omic dataset. Other studies have used non-
linear ML models, such as random forest, to predict disease
severity from metabolomics, lipidomics, and/or proteomics pro-
files.10,12,19 While those studies found higher AUC scores than
that of ourmodel, they used considerably smaller patient cohorts
than what our model was trained and evaluated on. Further, AUC
scores are not directly comparable, unless they are calculated
from the same dataset. When we tested non-linear models (sup-
port vectormachines and random forest), we foundworse cross-
validated performance relative to ElasticNet (see Figure S4C).
Interpretation of our model led us to identify metabolites that
predicted disease severity. Using a reduced predictor set, we
were able to retrain our model and found similarly strong predic-
tive ability. Of the predictor metabolites, most were LPCs and
PCs that were more decreased in patients with severe COVID-
19 when compared to patients with non-severe disease. The
observation that LPC and PC levels are altered in patients with
COVID-19 has been corroborated by multiple studies from
around the world. Early studies of COVID-19 patients from China
and Italy showed a decrease in PC levels and an increase in
select LPCs,14,32,60 but recent studies from South America and
Canada have shown that both circulating PC and LPC levels
decrease in patients with COVID-19.10,19 Not only do our results
support that PCs and LPCs are directly related to COVID-19 dis-
ease severity, they also build upon previous findings by showing
that these metabolites are decreased early in the disease course
and are, therefore, predictive of ICU admission. Additionally,
upon disease recovery, we find that LPCs are restored to the
levels of control individuals. We also confirmed that PCs and
LPCs are decreased in a hamster model of SARS-CoV-2 infec-
tion and that the levels of those metabolites in animal plasma
similarly recover over time.
The cellular mechanisms underlying the decreased LPC and
PC levels in the plasma of patients with severe COVID-19 may
be connected to uncontrolled inflammatory responses or viral
pathogenesis. Multiple studies have shown that individuals
with severe COVID-19 display a hyper-inflammatory state char-
acterized by dysregulated production of cytokines, such as IL-1,
IL-6, IL-10, and others.61–63 Fatty acids in plasma have also been
correlated with sustained IL-6 release and renal dysfunction in a
smaller cohort of patients with COVID-19,11 suggesting that
altered inflammatory responses may affect levels of circulating
metabolites. Consistent with prior studies, in our cohort, we
found that PC and LPC levels in patients with COVID-19 corre-
lated with inflammatory markers (e.g., IL-6, CRP, lymphocyte,
and neutrophil levels). In addition, reductions in circulating LPC
levels have also been found in patients with pneumonia-induced
inflammation, infection of the lung,64 and sepsis in which a cyto-
kine storm occurs.65 Alternatively, metabolic alterations may be
directly related to the pathogenesis of SARS-CoV-2. Reprog-
ramming of cellular metabolism is critical to sustain viral replica-
tion during coronavirus infection.66,67 SARS-CoV-2-infected
monocytes upregulate genes involved in lipid biosynthesis and




lipid remodeling, leading to the formation of lipid droplets.68
Additionally, a CRISPR-based screen for host factors required
for the replication of coronaviruses identified genes involved in
the sterol regulatory-element binding-protein (SREBP) pathway
and the gene encoding the low-density lipoprotein (LDL) recep-
tor. The SREBP pathway regulates cholesterol metabolism, and
the LDL receptor influences circulating lipid levels.69 As such, the
alterations in plasma metabolites found in our study may reflect
systemic alterations in metabolism induced by sustained viral
replication, especially in severe disease.
In summary, our large sample size that included longitudinal
measurements of patient plasma, collection of patient metadata
(laboratory values, comorbidities, and demographics), and use
of an animal model allowed us to discover a small panel of
metabolite predictors for COVID-19 severity and rigorously
investigate the relationship of thosemetabolites to the pathology
associated with SARS-CoV-2 infection. The model we present
here to assess the risk of a severe case of COVID-19 does not
require intensive computation or untargeted metabolomics,
making it immediately applicable to most hospitals around the
world. The metabolites presented could, for example, be quan-
titatively measured by triple quadrupole mass spectrometers,
which are widely available in clinical laboratories.
Limitations of the study
Although the size of our patient cohort is a major strength of this
study, sample collection started early in the pandemic (March
2020), when the appropriate treatment of SARS-CoV-2 infec-
tions was not yet established. Over the time of study enrollment,
treatment plans changed (e.g., fewer individuals were treated by
mechanical ventilation in the second half of the study). Addition-
ally, although the goal was to collect longitudinal samples 3, 7,
14, 28, and 84 days after initial sample collection, we were un-
able to obtain samples from all patients at every time point. Sub-
jects were less likely to provide plasma after being discharged
from the hospital, and samples could not be collected after pa-
tients were deceased. Moreover, even though the d0 sample
would ideally have been taken at or preceding hospital admis-
sion, this was not always possible. Some patients enrolled in
the study several days after being admitted, or they were
enrolled only after being transferred from another hospital. These
practical challenges affected the statistical power of our tempo-
ral comparisons. Furthermore, it is important to note that the pa-
tients studied here were all from hospitals in the St. Louis region
and were mostly collected before the emergence of variants,
such as B.1.617.2 (delta). Further longitudinal studies of patients
from other geographic regions who have been infected with var-
iants are thus needed to confirm the broad applicability of our
findings.
STAR+METHODS
Detailed methods are provided in the online version of this paper
and include the following:
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Supplemental information can be found online at https://doi.org/10.1016/j.
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REAGENT or RESOURCE SOURCE IDENTIFIER
Bacterial and Viral vectors
H1N1 influenza A virus
(A/California/04/2009)
NIH N/A
SARS-CoV-2 (WA-1) BEI Resources Cat# NR-52281
Biological samples
Human plasma samples Washington University in St. Louis,





Reference human plasma National Institue of Standards
and Technolgoy
SRM1950
Chemicals, peptides, and recombinant proteins
Acetonitrile LC/MS OPTIMA Fisher Scientific Cat#A955 4, CAS 75-05-8
Euthanasia Solution SleepAway Fort Dodge Animal Health NAC No.: 10031902
Formic Acid for LC-MS LiChropur Sigma-Aldrich Cat#5438040100, CAS 64-18-6
Ketamine Vedco, Inc., St Joseph, MO NDC 50989-996-06
Xylazine Akorn, Inc., Lake Forest, IL N/A
Mass Spectrometry Metabolite Library IROA Technologies Cat#MSMLS
Medronic Acid Sigma-Aldrich Cat#64255, CAS 1984-15-2
Methanol LC/MS OPTIMA Fisher Scientific Cat#A456 4, CAS 67-56-1
Methyl tert-butyl ether HPLC Plus Fisher Scientific Cat#650560, CAS 1634-04-4
OPTIMA LC/MS 2-propanol (IPA) Fisher Scientific Cat#A461 4, CAS 67-63-0
Water LC/MS OPTIMA Fisher Scientific Cat#W64, CAS 7732-18-5
Deposited data















LVG golden Syrian hamsters Charles River Laboratories (Kingston, NY) LVG(SYR)
Software and algorithms
Biorender BioRender.com RRID:SCR_018316
GraphPad Prism v3.8 GraphPad RRID:SCR_002798
Lipid Annotator v1 B1.0.54.0 Agilent Technologies N/A
Mass Profiler Professional Software v15.5 Agilent Technologies N/A
MassHunter Workstation LC/MS Data
Acquisition v10.1 B10.1.48
Agilent Technologies N/A
Python v3.7 python RRID:SCR_008394
Scikit-learn v0.23.1 N/A https://scikit-learn.org
SciPy v1.4.1 N/A https://SciPy.org
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Further information and requests for resources and reagents should be directed to the lead contact, Dr. Gary J. Patti (gjpattij@wustl.
edu).
Materials availability
This study did not generate new unique reagents.
Resources used in this study are available to the scientific community upon request from Dr. Gary J. Patti (gjpattij@wustl.edu).
Data and code availability
The raw LC/MS data as well as the processed metabolic profiles and corresponding metadata for the human (deidentified) and an-
imal samples is publicly available on the Metabolomics Workbench repository (NMRD:ST001849, ST001853; https://doi.org/10.
21228/M80981). Custom code used to perform the ML analyses is available on GitHub (https://github.com/e-stan/
covid_19_analysis)
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human subjects and samples
Over the period of March to August of 2020, blood specimens of 341 individuals who presented at Barnes Jewish Hospital or Chris-
tian Hospital located in Saint Louis, Missouri, USAwere collected. Inclusion criteria were a physician-ordered SARS-CoV-2 nasopha-
ryngeal swab polymerase chain reaction (PCR) test with a positive or negative outcome, availability of gender and age information,
and an age greater than 18. Informed consent was obtained from all study participants. The clinical cohort consisted of 155 female
and 184 male participants. Out of the 339 patients, 272 were considered SARS-CoV-2 positive (COV+) and 67 were considered
SARS-CoV-2 negative (COV-). Samples were collected at the time of enrollment (d0) to the study, and 3, 7, 14, 28, or 84 days
post study entry. Clinically relevant medical information (e.g., patient-reported symptoms, date of symptom onset, age, race, and
BMI) was collected at the time of enrollment from the subject or from the medical record. Data were retrieved for the current study
on October 16th 2020.
Animal studies
All animal studieswere performed atMount Sinai School ofMedicine. Outbred female LVGgolden Syrian hamsters (6-8weeks of age)
were obtained from Charles River Laboratories (Kingston, NY). Experiments were performed as previously published.25,56 In short,
the hamsters were anesthetized by intraperitoneal injection of a mixture of ketamine and xylazine prior to intranasal inoculation with
0.1mL of 1e5 plaque-forming units (PFU) of SARS-CoV-2 (WA-1) or H1N1 influenza A virus (A/California/04/2009). On day 2, 4, 6, and
14 after infection, 3-6 anesthetized hamsters per infection group were euthanized by exsanguination followed by intracardiac injec-
tion of veterinary euthanasia solution (SleepAway; Fort Dodge). Plasma samples were exposed to germicidal UV-C light. A disease
score was calculated based on virology and weight-loss data.
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Skyline 64-bit v20.2.0.343 MacCoss Lab Software RRID:SCR_014080
statsmodels v0.11.1 N/A https://statsmodels.org
Thermo Scientific Xcalibur v4.2.28.14,
AcquireX workflow
Thermo Fisher Scientific RRID:SCR_014080
Other
ACQUITY UPLC HSS T3 Column, 100Å,
1.8 mm, 2.1 mm X 150 mm
Waters Cat#186003540
VanGuard Pre-Column HSS T3, 1.7 mm,
2.1mm x 5mm
Waters Cat#186003976
SeQuant ZIC-pHILIC HPLC Column,
5mm polymer 100 3 2.1 mm
Merck Millipore Cat#150462
SeQuant ZIC-pHILIC Guard Kit,
5mm polymer 20 3 2.1 mm
Merck Millipore Cat#150438





Portions of the human study relevant to Barnes Jewish Hospital, Christian Hospital, and Washington University were reviewed and
approved by the Washington University in Saint Louis Institutional Review Board (WU-350 study approval #202003085, and plasma
metabolomics study approval #202004204). All animal studies were approved by the Institutional Care and Use Committee at Mount
Sinai School of Medicine, following the humane care and use guidelines set by the institution.
METHOD DETAILS
Metabolomics sample preparation
Participant plasma, which had been stored at80C upon collection, was thawed on ice. A 50 mL aliquot was transferred onto a solid-
phase-extraction (SPE)-system CAPTIVA-EMR Lipid 96-wellplate (Agilent Technologies) before addition of 250 mL of acetonitrile con-
taining 1% formic acid (v/v) and 10 mM internal standard (consisting of uniformly 13C and 15N labeled amino acids from Cambridge
Isotope Laboratories, Inc). The samples were mixed for 1 min at 360 rpm on an orbital shaker at room temperature prior to a 10 min in-
cubationperiodat4C.Afterward,200mL80%acetonitrile inwater (v/v)wasadded to thesamples.Thesamplesweremixedonanorbital
shaker (360 rpm) for an additional 10 min at room temperature. The samples were then eluted into a 96-deepwell collection plate by
centrifugation (10min, 57 x g, 4C followed by 2min, 1000 x g, 4C). Polar eluateswere stored at80Cuntil the day of LC/MS analysis.
The SPE-plateswere thenwashed twice with 500 mL 80%acetonitrile in water (v/v). Lipids still bound to the SPE-material were then
released into a second elution plate, in two elution steps applying 2x 500 mL 1:1 methyl tert-butyl ether:methanol (v/v) onto the SPE
cartridge and centrifuging for 2min at 1000 g and 4C. The combined eluates were dried under a stream of nitrogen (Biotage SPE Dry
Evaporation System) at room temperature and reconstituted with 100 mL 1:1 2-propanol:methanol (v/v) prior to LC/MS analysis.
Hamster plasma samples were diluted 1:4 with methanol (v/v), vortexed for 30 s, and incubated at 20C for 2 hours. Samples
were centrifuged for 10 minutes at 13,500 x g at 4C and supernatant was transferred to a new centrifuge tube, concentrated,
and stored at 80C until reconstitution as described above.
LC/MS analysis of polar metabolites
A 2 mLaliquot of polar metabolite extract was subjected to LC/MS analysis by using an Agilent 1290 Infinity II liquid-chromatography
(LC) system coupled to an Agilent 6540Quadrupole-Time-of-Flight (QTOF)mass spectrometer with a dual Agilent Jet Stream electro-
spray ionization source. Polar metabolites were separated on a SeQuant ZIC-pHILIC column (100 3 2.1 mm, 5 mm, polymer,
Merck-Millipore) including a ZIC-pHILIC guard column (2.1 mm x 20 mm, 5 mm). The column compartment temperature was main-
tained at 40C and the flow rate was set to 250 mL$min-1. The mobile phases consisted of A: 95% water, 5% acetonitrile, 20 mM
ammonium bicarbonate, 0.1% ammonium hydroxide solution (25% ammonia in water), 2.5 mM medronic acid, and B: 95%
acetonitrile, 5% water, 2.5 mM medronic acid. The following linear gradient was applied: 0 to 1 min, 90% B; 12 min, 35% B; 12.5
to 14.5 min, 25% B; 15 min, 90% B followed by a re-equilibration phase of 4 min at 400 mL$min1 and 2 min at 250 mL$min1. Me-
tabolites were detected in positive and negative ion mode with the following source parameters: gas temperature 200C, drying gas
flow 10 L$min1, nebulizer pressure 44 psi, sheath gas temperature 300C, sheath gas flow 12 L$min1, VCap 3000 V, nozzle voltage
2000 V, Fragmentor 100 V, Skimmer 65 V, Oct 1 RF Vpp 750 V, and m/z range 50-1700. Data were acquired under continuous refer-
ence mass correction at m/z 121.0509 and 922.0890 for positive ion mode and m/z 119.0363 and 966.0007 for negative ion mode.
Samples were randomized prior to analysis. In addition, a quality control sample was injected after every 12th sample to monitor
signal stability of the instrument.
LC/MS analysis of lipid metabolites
A 2 mL aliquot of lipid metabolite extract was subjected to LC/MS analysis by using an Agilent 1290 Infinity II LC-system coupled to an
Agilent 6545 QTOF mass spectrometer with a dual Agilent Jet Stream electrospray ionization source. Lipids were separated on an
Acquity UPLC HSS T3 column (2.1 3 150 mm, 1.8 mm) including an Acquity UPLC HSS T3 VanGuard Pre-Column (2.1 3 5mm,
1.8 mm) at a temperature of 60C and a flow rate of 250 mL$min1. The mobile phases consisted of A: 60% acetonitrile, 40% water,
0.1% formic acid, 10 mM ammonium formate, 2.5 mM medronic acid, and B: 90% 2-propanol, 10% acetonitrile, 0.1% formic acid,
10mM ammonium formate (dissolved in 1mLwater). The following linear gradient was used: 0-2min, 30%B; 17min, 75%B; 20min,
85% B; 23-26 min, 100% B; 26 min, 30% B followed by a re-equilibration phase of 5 min.
Lipids were detected in positive and negative ion mode with the following source parameters: gas temperature 250C, drying gas
flow 11 L$min1, nebulizer pressure 35 psi, sheath gas temperature 300C, sheath gas flow 12 L$min1, VCap 3000 V, nozzle voltage
500 V, Fragmentor 160 V, Skimmer 65 V, Oct 1 RF Vpp 750 V, and m/z range 50-1700. Data were acquired under continuous refer-
ence mass correction at m/z 121.0509 and 922.0890 in positive ion mode and m/z 119.0363 and 966.0007 in negative ion mode.
Samples were randomized before analysis. In addition, a quality-control (QC) sample was injected after every 12th sample to monitor
signal stability of the instrument.
Data preprocessing and normalization
Polar metabolite identifications were supported by matching the retention time, accurate mass, and MS/MS fragmentation data to
our in-house retention time and MS/MS library created from authentic reference standards (Mass Spectrometry Metabolite Library




supplied by IROA Technologies, Millipore Sigma, St. Louis, MO, USA) and online MS/MS libraries (Human Metabolome Database
(HMDB, https://hmdb.ca 70), Mass Bank of North America (MoNA, https://mona.fiehnlab.ucdavis.edu/ 71), and mzCloud (https://
www.mzcloud.org). Lipid iterative MS/MS data were annotated with the Agilent Lipid Annotator software. All data files were then
analyzed in Skyline (Version 20.1.0.155) to obtain peak areas. m/z values of the metabolite and lipid target lists obtained from the
metabolite identification workflow, which had at least an MS/MS match to an online library, were extracted under consideration
of retention times.
Due to the risk of handling plasma samples fromSARS-CoV-2-positive patients and not knowing howmany batches of samples we
would receive, we refrained from preparing a pooled sample and instead used the NIST SRM1950 plasma referencematerial as aQC
sample in each batch. The QC sample was injected after every 12th sample. After peak area extraction, batch effects were observed
in the research samples (see Figure S2A). The research samples and QC data were used to test typical batch normalization methods
(see Figure S2B), including constant sum, unit length, scale, percentile shift, minimum-maximum, probabilistic quotient normaliza-
tion, quantile, and ComBat correction used in metabolomics.29,72–75 In Figure S2B, the variance remaining in the research samples
normalized to the variance in the QC samples is shown for each method. The higher this ratio, the more variance that remains in the
research samples and the more batch-derived variance in the QC samples is reduced. ComBat correction outperformed the other
batch-correction approaches tested by using this metric. After correction, samples are well clustered according to sample type (WU-
350, QC, blank) as shown in Figure S2C. In addition, within the research samples, there is no clustering by batch (see Figure S2D).
Machine learning
Samples were split into two distinct cohorts for training and testing theMLmodel. d0 COV+ patient samples within batches 1-6made
up the training set and d0 COV+ patient samples from batches 7 through 9 made up the test set. Training and tests sets were treated
independently except for batch normalization, which was carried out for all patients (including samples collected after d0 and COV-
samples) together. Demographics of both training and tests sets are available in Tables S1 and S2.
Model selection was based on 20-fold cross validation of the training set. Five different ML models: logistic regression, ElasticNet
linear regression, partial least-squares discriminant analysis (PLSDA), support vector machine (SVM), and random forest were
selected for consideration based on interpretability and previous studies.10,12,59,76 Hyperparameters of all models and feature selec-
tion strategies were optimized by using 20-fold cross validation and a grid search. Two separate feature selection strategies were
tested: a correlation-based approach and a statistic-based approach. In the correlation-based approach, the Pearson correlation
was computed between each metabolite’s intensity and disease severity. Then, the top X% of metabolites sorted by absolute cor-
relation was taken as the predictors for theMLmodel. In the statistic-based approach, a Student’s t test was performed to assess the
statistical significance of the differences in each metabolite’s intensity between COV+ severe and COV+ non-severe patients. Abso-
lute fold-change and p value cutoffs were used to select metabolites. Performance was assessed with the area under the receiver
operating characteristic curve (AUC). After optimization, ElasticNet regression achieved the highest AUC on the cross validated
training dataset. The ElasticNet model is given below in Equation 1, where X is the matrix of metabolic profiles (# of samples by #
of metabolites), b is the bias term, y is the sample labels (0 = COV+ non-severe, 1 = COV+ severe),w is the weight of eachmetabolite









After optimization, the correlation-based feature selection was used by taking the top 33% most correlated metabolites and model
hyperparameters were set to a= 10:0 and r = 0:0. In the reduced predictor model, no feature selection was performed and model
hyperparameters were set to a= 1:0 and r = 0:0.
The variable importance of eachmetabolite in the ElasticNet model is easily computed from the optimizedweights,w. To normalize
for the different abundances of the metabolites, each weight was normalized by the median abundance of the metabolite across all
samples. The more positive the variable importance, the more predictive that metabolite is to severe disease. The more negative the
variable importance, the more predictive the metabolite is to non-severe disease. To find the metabolites that significantly contribute
to the model fit, the training dataset was resampled with replacement 10,000 times. At each iteration, the ElasticNet model was
trained and the variable importance was calculated. After the iterations were complete, the 95% confidence interval of the variable
importance was calculated for each metabolite by using the 2.5 and 97.5 percentiles. If this interval included zero, the metabolite did
not significantly contribute to the model fit.
All ML analyses were carried out by using Python (v3.7), with extensive use of the packages SciPy (v1.4.1)77 and Scikit-learn
(v0.23.1).78
Controlling for disease severity
To control for disease severity in the correlation analysis of the predictor metabolites, interleukin levels, and patient parameters
(laboratory results, comorbidities, demographics), the mean value within each patient group (COV+ severe, COV+ non-severe,
and COV-) was subtracted from each patient’s metabolite levels, interleukin levels, and patient parameters. This prevents weak
correlations from occurring as a result of bulk changes associated with disease severity. After correction, the Pearson correlations
between each corrected metabolite/interleukin measurement and patient parameter were calculated.




Confirming metabolite identities of predictor metabolites
The identities of the predictor metabolites were rigorously confirmed with authentic standards. For the polar compounds, authentic
standards were purchased to not only match MS/MS spectra but also retention times. For lipids, one or two standards per lipid class
were matched to an authentic standard to compare MS/MS spectra and retention times. PCs were identified based on m/z and the
two characteristic fragments 184.0733 and 86.0964 in positive ionization mode. For PCs where no peaks for the acyl-chains were
observed, only the sum composition can be given. PEs were identified based on the neutral loss of phosphorylethanolamine
(141.0191) in positive mode. The fatty acyl composition could be derived from the spectra, but no differentiation of regioisomers
was possible, as was the case for ceramides. To denote regiospecificity, metabolites whose regioisomers could be differentiated
have their acyl-chains separated with a ‘‘/’’ while those that could not have a ‘‘_.’’ Cer-NS d18:1_16:0 was matched to its authentic
standard. MS/MS data for Cer-NS d18:2_16:0 were matched to MS/MS library spectra. Cer-NS d18:3_16:0 eluted slightly before
Cer-NS d18:1_16:0, as expected due to having one less double bond. LPCs were identified based on MS/MS spectral matches.
Standards were available for LPC 14:0/0:0 and LPC 18:1/0:0. Their retention times were used as a reference for the other LPCs.
The two regioisomers of LPCs (sn1 and sn2) were separated by liquid chromatography, with the sn1 isomer eluting later. They are
also distinguished by their MS/MS spectra. 1-acyl-LPC (sn1) shows two main fragments (m/z 184.0733 and 104.1070), whereas
the 2-acyl-LPC (sn2) has a more pronounced 184.0733 fragment. The 104.1070 fragment (choline) has been previously reported
as being more abundant from sodiated LPCs.79 We note that sn2 LPCs can be converted to sn1 during sample preparation, and
our sample preparation was not dedicated to preserve isomers.80,81
Acquiring MS/MS data
MS/MS spectra for polar metabolites and lipids were acquired by using an iterative approach in theMassHunter Acquisition Software
(Version 10.1.48, Agilent Technologies) on an Agilent 6540 and 6545 QTOF, respectively. The same source settings as for MS1 data
acquisition were used. MS/MS spectra were acquired at a scan rate of 3 spectra/s with different intensity thresholds and collision
energies of 10, 20, and 40 V to increase identification rates.
To improve matching to Orbitrap spectral databases, MS/MS data for polar metabolites were acquired on an Orbitrap ID-X Tribrid
mass spectrometer (Thermo Scientific). A Vanquish Horizon UHPLC system, with the same chromatographic conditions as
described in the Method details, was interfaced with the mass spectrometer via electrospray ionization in both positive and negative
ion mode with a spray voltage of 3.5 and 2.8 kV, respectively. The RF lens value was 35%. Data were acquired in data dependent
acquisition (DDA) mode by using the built-in deep scan option (AcquireX) with a mass range of 67-900 m/z. MS/MS scans were ac-
quired at 15K resolution on a NIST SRM 1950 plasma sample and from 4 individual samples (d0, d3, d7, and d14) in both positive and
negative ion mode with different collision energies in the range of 20 NCE to 50 NCE for HCD and 30 NCE for CID to maximize
identifications.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analysis
All statistical analyses were performed by using the SciPy (v1.4.1)77 and statsmodels (v0.11.1)82 Python packages and with the Mass
Profiler Professional Software (Agilent Technologies, v15.5). All p values were corrected for multiple hypothesis testing by using the
Benjamini-Hochberg procedure.83 All statistical tests used are described in the figure legends.
Permutation test
To assess the significance of themodel fit and compare the predictive power towhat is expected from randomchance, we performed
a permutation test. After the feature selection and model hyperparameters were optimized, the training dataset labels were
permuted, and the model was retrained on the permuted data. Then, the performance of the model was assessed on the non-
permuted test set and the AUC was computed. This process was repeated 1,000 times. The empirical p value was computed by
calculating the percentage of the 1,000 permutations that achieved an AUC higher than that of themodel’s performancewhen trained
on non-permuted data.
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Figure S1. Age, BMI, and symptom characteristics of the patient cohort.  (A) Age distribution of SARS-CoV-2-
negative (COV-) and SARS-CoV-2-positive (COV+) patients, including the age span indicated as minimum (min) 
and maximum (max) age for each group. (B) BMI distribution of both COV- and COV+ groups. (C) Percentage of 
COVID-19 related symptoms in both the COV- and COV+ groups. (D-E) Breakdown of the number of COVID-19-





Figure S2. Batch effects and normalization. (A) Principal component analysis (PCA) plot of metabolic profiles of 
all research (WU-350), quality-control (QC), and blank samples shows strong batch effects. The color of each dot 
represents the batch of each sample. (B) Comparison of 10 different batch normalization methods. The y-axis shows 
the variance remaining in the research samples normalized by the QC variance. (C) After ComBat normalization, the 
PCA plot shows samples cluster by origin (WU-350, QC, blank). (D) After ComBat normalization, there is no 





Figure S3. Clustering of d0 patient samples. Heatmap of metabolite intensities for compounds that are 
significantly different (p<0.05, Welch’s ANOVA) clustered by samples and metabolites. The color of each column 




Figure S4. Cohort details, model selection and evaluation. (A) Timing of ICU admission relative to d0 and 
symptom onset. (B) Time from symptom onset to d0 sample. There is no significant difference in time from 
symptom onset to d0 sample between COV+ severe and COV+ non-severe patients. (C) 20-fold cross validation of 
the training dataset was used to select the best modeling framework. The score on the y-axis represents the area 
under the receiver operating characteristic curve (AUC). An ElasticNet model achieved the highest cross-validated 
performance. (D) ElasticNet output when model was trained with all profiled metabolites and the training cohort. 
The scores for the individuals in the test cohort are broken down by disease status. Box limits represent the quartiles 





Figure S5. Clustering of full prediction model metabolites. Hierarchical clustering analysis of the 92 prediction 
model metabolites and the mean metabolic profile for COV- (n=59), COV+ non-severe (n=140), and COV+ severe 





Figure S6. Model performance using the highly salient metabolites as predictors. (A) Performance on different 
sets is assessed via ROC curves (x-axis fpr = false positive rate; y-axis tpr = true positive rate) for the training set 
(green), test set (blue), and baseline performance when only BMI and age are used as predictors for severe COVID-
19 disease (red). Random performance is shown in gray. (B) The significance of the model’s fit is computed by 
using a permutation test with n=1000 giving an empirical p value of 0.011. (C) Performance on the subset of test-set 
patients not admitted to the ICU on or before d0 is assessed via ROC curves for the training set (green), test set 
(blue), and baseline performance when only BMI and age are used as predictors for severe COVID-19 disease (red). 
Random performance is shown in gray. (D) The significance of the model’s performance for the test set is computed 





Figure S7. Clustering of predictor metabolites. Hierarchical clustering analysis of the predictor metabolites and 
the mean metabolic profile for COV- (n=59), COV+ non-severe (n=140), and COV+ severe patients (n=123). 





Figure S8. Comparison of metabolic profiles within patient subsets. (A) Predictor metabolite intensities for 
COV- (n=59), COV+ non-severe (n=60), and COV+ severe (n=40) patients in the test set. (B) Predictor metabolite 
intensities for COV- (n=59), COV+ non-severe (n=140), and COV+ severe (n=20) patients not admitted to the ICU 
on or before d0. Box limits represent the quartiles of each sample group. Whiskers are drawn to 1.5x of the inter-







Figure S9. Comparison of metabolic profiles for deceased and surviving COV+ patients. Predictor metabolite 
intensities in COV+ non-severe, surviving COV+ severe patients, and deceased COV+ severe patients compared to 
the d0 COV- patients at different times relative to symptom onset. COV+ non-severe patients’ metabolite levels 
recover more quickly than surviving COV+ severe patients. Diseased and surviving status was based on 90-day 
mortality. Samples taken from asymptomatic individuals and on days when dexamethasone or remdesivir were 
administered were excluded. * indicates a p value < 0.05. Statistical significance was assessed by using a one-way 
Welch’s ANOVA with Benjamini-Hochberg correction. Box limits represent the quartiles of each sample group. 
Whiskers are drawn to 1.5x of the inter-quartile range. Related to Figure 4B and 5.       
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Figure S10. Composite clinical score for Syrian hamster model. The scores reflect the following parameters. 
Score of 1: body weight loss of 0.1% to 5%; score of 2: body weight loss of 5.1% to 10%; score of 3: body weight 
loss of 10.1% to 15%; score of 4: body weight loss of 15.1% to 20%; score of 1: lung viral titers; and score of 1: 





Figure S11. Metabolite levels in hamster samples over four time points. (A) Metabolite levels in SARS-CoV-2-
infected animals show pronounced changes over disease course but did not reach significance threshold. (B) Mock 
samples show non-significant time-dependent variation. (C) Influenza-infected animals show longitudinal changes 
with only two predictor metabolites significantly varying. Statistical significance was assessed by using a one-way 
Welch’s ANOVA with Benjamini-Hochberg correction. * indicates a p value < 0.10. ** indicates a p value less than 
0.05. Box limits represent the quartiles of each sample group. Whiskers are drawn to 1.5x of the inter-quartile range. 
Related to Figure 6.    
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Table S1. Demographics of training cohort. Related to Table 1. 
Parameter COV- COV+ p value 
N 37 163  
Gender (M/F) 13/24 94/69 p=0.0130 
Age (years) 49.32 ± 18.05 62.88 ± 15.87 p<0.0001 
Age range (years)  19.6 - 87.6 19.2 - 92.7  
Race (African American/White/other) 16/21/0 125/37/1 p<0.0001 
Body mass index 29.97 ± 7.221 29.93± 8.050 p=0.9511 
COVID19-like symptoms4    
 any number of COVID19-like symptoms 37 149 p=0.0645 
 Fever 14 86 p=0.1012 
 Chills 10 22 p=0.0427 
 Conjunctival congestion 0 1 p=0.6329 
 Nasal congestion 3 7 p=0.3366 
 Headache 11 13 p=0.0002 
 Cough 22 95 p=0.8956 
 Sore throat 7 12 p=0.0304 
 Shortness of breath 25 99 p=0.4396 
 Nausea or vomiting 9 23 p=0.1260 
 Diarrhea 7 21 p=0.3395 
 Myalgia 8 40 p=0.7075 
 Fatigue 15 31 p=0.0050 
 Loss of taste or smella 0 1 p=0.6329 
 Asymptomaticb NA 6  
Acute respiratory failurec 5  65 p=0.0024 
Acute renal failurec 2 51 p=0.0013 
Comorbidities     
 Chronic Kidney Diseased 3 32 p=0.0958 
 Diabetesd 9 78 p=0.0092 
 Cancerd  5 12 p=0.2258 
COVID-19 treatmente    
 Remdesivir 1 7 p=0.6556 
 Dexamethasone 6 12 p=0.0893 
Low/High Arterial pH 4 50 p=0.0140 
Current Smoker 9 (24%) 18 (11.5%) p=0.0328 
Hospital Admissionf  14 (37.8%) 152 (92.7%) p<0.0001 
ICU Admissionf 6 (16.2%) 83 (50.3%) p=0.0001 
Intubation and Mechanical Ventilation  3 (8.1%) 40 (27.9%) p=0.0281 
Deceased 4 (10.8%) 43 (26.1%) p=0.0438 
Deceased because of Covid-19g    
 30 day mortality N/A 29 (85.3%)  
 60 day mortality N/A 34 (100%)  
 90 day mortality N/A 34 (100%)  






Table includes only d0 samples of the training cohort. Percentages are shown as the percentage of the group (COV- or COV+). Data last updated May 26, 2021. 
Data are presented as mean ± standard deviation, p values of numeric parameters were calculated by using a 2-tailed Student’s t test with unequal variance, and p 
values of categorical parameters were calculated by using a chi-square test. Abbreviations: M, male; F, female; N/A, not applicable. 
 
a Eight SARS-CoV-2-positive individuals had other symptoms (e.g., confusion, lethargy, an altered mental state, or breathing anomalies). Data last updated 
October 16, 2020.  
b CDC guideline symptom was added to the symptom questionnaire late in the study; parameter is not available for the majority of the subjects. 
c SARS-CoV-2 test was routinely administered at presentation to the hospital. The latter was for reasons other than COVID-19 (e.g., accidents, pre-operation tests, 
regular check-ups, cancer screening, injuries, exposure to a SARS-CoV-2-positive individual). 
d During present hospitalization. 
e Recorded up to one year prior to the current admission or up to one year prior to the d0 sample for those who were not admitted to the hospital.  
fAt any point during present hospital stay. 
g Hospital and/or ICU admission of COV- group for reasons other than COVID-19 (e.g., accidents, acute respiratory failure due to bacterial pneumonia, 
intentional self-harm, possible heart failure, hypertension, trauma, cancer). 
h Percentages shown as % of total deceased. 
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Table S2. Demographics of test cohort. Related to Table 1. 
Parameter1,2,3 COV- COV+ p value 
N 22 100  
Gender (M/F) 10/12 56/44 p=0.3688 
Age (years) 42.40 ± 13.37 54.96 ± 18.12 p=0.0023 
Age range (years)  26.5 - 65.6 19.30 - 91.1  
Race (African American/White/other) 15/7/0 71/28/1 p=0.7408 
Body mass index 31.58 ± 10.18 33.73 ± 10.86 p=0.3979 
COVID19-like symptomsa    
 any number of COVID19-like symptoms 21 84 p=0.1601 
 Fever 10 35 p=0.3575 
 Chills 3 22 p=0.3789 
 Conjunctival congestion 0 0  
 Nasal congestion 3 3 p=0.0367 
 Headache 3 9 p=0.5085 
 Cough 9 48 p=0.5462 
 Sore throat 4 9 p=0.2063 
 Shortness of breath 15 61 p=0.5292 
 Nausea or vomiting 6 16 p=0.2131 
 Diarrhea 3 15 p=0.8703 
 Myalgia 7 24 p=0.4457 
 Fatigue 3 22 p=0.3789 
 Loss of taste or smellb 0 3 p=0.4107 
 Asymptomaticc NA 15  
Acute respiratory failured 4 28 p=0.3432 
Acute renal failured 0 11 p=0.1029 
Comorbidities     
 Chronic Kidney Diseasee 1 23 p=0.0487 
 Diabetese 6 38 p=0.3428 
 Cancere  2 11 p=0.7927 
COVID-19 treatmentf    
 Remdesivir 1 21 p=0.0691 
 Dexamethasone 7 29 p=0.7930 
Critically Low/High Arterial pH 1 27 p=0.0234 
Current Smoker 9 (40.9%) 16 (16.0%) p=0.0088 
Hospital Admissiong 12 (54.5%) 91 (91.0%) p<0.0001 
ICU Admissiong 4 (18.2%) 40 (40.0%) p=0.0537 
Intubation and Mechanical Ventilation  1 (4.5%) 24 (24.0%) p=0.0407 
Deceased 2 (9.1%) 20 (20.0%) p=0.2282 
Deceased because of Covidh    
 30 day mortality N/A 8 (53.3%)  
 60 day mortality N/A 13 (86.7%)  
 90 day mortality N/A 14 (93.3%)  






Table includes only d0 samples of the test cohort. Percentages are shown as the percentage of the group (COV- or COV+). Data last updated May 26, 2021. Data 
are presented as mean ± standard deviation, p values of numeric parameters were calculated by using a 2-tailed Student’s t test with unequal variance, and p values 
of categorical parameters were calculated by using a chi-square test. Abbreviations: M, male; F, female; N/A, not applicable. 
a One SARS-CoV-2-positive individual had other symptoms (loss of appetite, syncopal episodes). Data last updated October 16, 2021.    
b CDC guideline symptom was added to the symptom questionnaire late in the study; parameter is not available for the majority of the subjects. 
cSARS-CoV-2 test was routinely administered at presentation to the hospital. The latter was for reasons other than COVID-19 (e.g., accidents, pre-operation tests, 
regular check-ups, cancer screening, injuries, exposure to a SARS-CoV-2-positive individual). 
d During present hospitalization. 
e Recorded up to one year prior to the current admission or up to one year prior to the d0 sample for those who were not admitted to the hospital.  
f At any point during present hospital stay. 
g Hospital and/or ICU admission of COV- group for reasons other than COVID-19 (e.g., accidents, acute respiratory failure due to bacterial pneumonia, intentional 
self-harm, possible heart failure, hypertension, trauma, cancer). 
h Percentages shown as % of total deceased.  
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Table S3.  Demographics, comorbidities and laboratory values of SARS-CoV-2-infected individuals 
with d0 sample available. Related to Figure 3. 
Parameter COV+ non-severe COV+ severe p value 
n 140 123  
Gender (M/F) 73/67 77/46 p=0.0873 
Age (years) 55 ± 17 66 ± 15 p<0.0001 
Age range (years) 19.2 - 92.7 19.3 - 90.8  
Race (African American/White/other) 108/30/1 88/35/0 p=0.2140 
BMI 32 ± 9 30 ± 10 p=0.1119 
Current smoker 23 11 p=0.0710 
Deceased 11 52 p<0.0001 
Deceased due to COVID-19 3 46 p<0.0001 
Acute respiratory failurea 16 77 p<0.0001 
Acute renal failurea 14 48 p<0.0001 
Comorbidities    
 Chronic kidney diseaseb 24 31 p=0.1088 
 Diabetesb 51 65 p=0.0075 
 Cancerb 11 12 p=0.5865 
Laboratory Results    
 High/Low arterial pH 1 76 p<0.0001 
 C-reactive protein (mg/L) 67.8 ± 65.45 (n=89) 154.6 ± 110.9 (n=101) p<0.0001 
 D-dimer (ng/mL FEU) 2614 ± 6839 (n=91) 5895 ± 10682 (n=103) p=0.0108 
 Neutrophil absolute (K/cumm) 4.842 ± 2.656 (n=133) 7.644 ± 5.602 (n=117) p<0.0001 
 Neutrophil (%) 67.23 ± 11.90 (n=133) 78.01 ± 12.10 (n=117) p<0.0001 
 Lymphocyte absolute (K/cumm) 1.450 ± 0.8166 (n=135) 0.9644 ± 0.5237 (n=118) p<0.0001 
 Lymphocyte (%) 21.91 ± 10.34 (n=135) 13.52 ±9.401 (n=118) p<0.0001 
  CO2, Total (mmol/L) 24.89 ± 3.77 (n=137) 24.10 ± 4.17 (n=122) p=0.1120 
COVID-19 drug treatment    
 Remdesivirc 7 17 p=0.0132 




Table includes both training and test cohorts. Data last updated May 20, 2021. Data are presented as mean ± standard deviation, p values of numeric 
parameters were calculated by using a 2-tailed Student’s t test with unequal variance; p values of categorical parameters were calculated by using a chi-square 
test. Abbreviations: M, male; F, female. 
aDuring present hospital admission. 
bRecorded up to one year prior to the current admission or up to one year prior to the d0 sample for those who were not admitted to the hospital. 
cAdministered on d0. 
 
